6 June 2017 - Cost regulators for the NHS in England and Wales are backing routine use of Allergan’s Ozurdex and AbbVie’s Humira to treat non-infectious posterior uveitis, a form of preventable vision loss.

NICE has published a final appraisal determination recommending the drugs as cost and clinically-effective treatment options for people with sight-threatening posterior non-infectious posterior uveitis.

Both Ozurdex (dexamethasone intravitreal implant) and Humira (adalimumab) are only recommended in the presence of active disease (that is, current inflammation in the eye) and worsening vision with a risk of blindness.

Read Pharma Times article